”It enables a whole new business model”
It is one thing that the potential in Genmab’s deal with Janssen has been doubled, but another crucial aspect of the deal is that it has a “huge impact” on the company’s future prospects, says Jan van de Winkel.
by Stefan Singh Kailay
When Genmab announced an expansion of its hugely important partnership deal with Janssen last week, it was also an announcement of a doubling of the already huge potential of the deal.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Official: Genmab enters elite index
For abonnenter
Biotech CEO: Front runners drive the sector
For abonnenter
Lundbeck eyes solid premium in Genmab field
For abonnenter
